The effect of esketamine on perioperative anxiety and depressive symptoms in patients undergoing total hysterectomy.
The journal of obstetrics and gynaecology research – May 01, 2025
Source: PubMed
Summary
A single dose of esketamine before surgery significantly improved emotional wellbeing in women undergoing total hysterectomy. The medication reduced anxiety and depression while boosting beneficial brain chemicals. Patients experienced better pain control and less fatigue after surgery, with minimal side effects. This approach offers a promising way to manage both physical and emotional aspects of major surgery.
Abstract
This study aimed to evaluate the effect of esketamine on perioperative anxiety and depressive symptoms, acute stress reaction, and serum neurotransmitters in patients undergoing total hysterectomy. Clinical data of 120 patients undergoing total hysterectomy from May 2020 to June 2021 were retrospectively analyzed and divided into group C (3 mL of saline administered intravenously 10 min before surgical excision, 65 patients) or group K (0.5 mg/kg of esketamine administered intravenously 10 min before surgical excision, 55 patients). Acute stress reaction, depression, and anxiety; and myeloperoxidase levels were lower while serum dopamine, 5-hydroxytryptamine, neuropeptide, as well as brain-derived neurotrophic factor levels were higher in group K than those in group C at 12 h postoperatively (p 0.05). In summary, as a preventive measure for patients undergoing total hysterectomy, esketamine can reduce perioperative anxiety and depression, result in good analgesic and sedative effects without significantly increasing adverse effects.